Mismatch Repair Gene
            <i>MSH3</i>
            Polymorphism is Associated With the Risk of Sporadic Prostate Cancer

Hirata, Hiroshi; Hinoda, Yuji; Kawamoto, Ken; Kikuno, Nobuyuki; Suehiro, Yutaka; Okayama, Naoko; Tanaka, Yuichiro; Dahiya, Rajvir

doi:10.1016/j.juro.2008.01.009

Cited by 33 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several genetic polymorphisms are considered to be molecular markers that predict the risk, progression and prognosis of various cancers (3)(4)(5)(6)(7). Indeed, single nucleotide polymorphisms (SNPs) in several genes are reported to be associated with the risk of lung cancer (8)(9)(10), for example SNPs in the caspase-3 and vascular endothelial growth factor genes (11,12).…”

Section: Introductionmentioning

confidence: 99%

The allelic distribution of a single nucleotide polymorphism in the PDCD5 gene locus of Japanese non-small cell lung cancer patients

Nanba

Toyooka²,

Soh³

et al. 2008

Mol Med Rep

View full text Add to dashboard Cite

Abstract. It has been reported that the rs1862214 single nucleotide polymorphism (SNP) in the programmed cell death 5 gene (PDCD5) is associated with smoking-related lung cancer risk and prognosis in a European population with a history of smoking. The aim of this study was to investigate the status and impact of SNPs in the PDCD5 locus of a Japanese population. We developed an assay based on realtime PCR with melting curve analysis for determining the rs1862214 SNP, and examined this SNP in 165 lung cancer patients and 180 healthy volunteers. Of the 165 lung cancer patients (107 smokers), 25 (17), 72 (47) and 68 (43) had the CC, CG and GG genotypes of rs1862214, respectively. Of the 180 volunteers (117 smokers), 31 (24), 81 (52) and 68 (41) had the CC, CG and GG genotypes of rs1862214, respectively. No significant difference in allelic distribution was found between Japanese patients and healthy controls, even among smokers. Based on the published data, the distribution of this SNP appears to be significantly different in Japanese and European populations. No significant difference in prognosis according to the SNP was observed, either in patients with a history of smoking or in the total number of patients. This too differs from the results from a European population. In conclusion, we developed a convenient real-time PCR-based assay for the genotyping of rs1862214 in the PDCD5 locus. The distribution of the rs1862214 SNP in our Japanese population differs from its distribution in a European population, and is not related to the risk of cancer or to poor prognosis in lung cancer. This suggests the presence of an ethnicity-related difference in the role of PDCD5 in the pathogenesis of lung cancer. IntroductionLung cancer is the leading cause of cancer death in Japan and many other countries worldwide (1,2). Survival among patients with non-small cell lung cancer remains unsatisfactory because many locally advanced or metastatic cases are unresectable. Even patients with the early stages of the disease who undergo complete resections often experience recurrence, resulting in an unfavorable prognosis. In short, until now the effectiveness of therapeutic strategies has been limited.In addition to aiding in the development of therapeutic strategies, the prevention or early detection of cancer improves its rate of mortality. Several genetic polymorphisms are considered to be molecular markers that predict the risk, progression and prognosis of various cancers (3-7). Indeed, single nucleotide polymorphisms (SNPs) in several genes are reported to be associated with the risk of lung cancer (8-10), for example SNPs in the caspase-3 and vascular endothelial growth factor genes (11,12).Recently, Spinola et al reported that the rs1862214 SNP in the programmed cell death 5 gene (PDCD5) locus, which is known to be involved in apoptosis (13,14), was associated with lung cancer risk and prognosis in a European population with a history of smoking (15). They performed a case-control study using German and Italian lung cancer pa...

show abstract

Section: Introductionmentioning

confidence: 99%

The allelic distribution of a single nucleotide polymorphism in the PDCD5 gene locus of Japanese non-small cell lung cancer patients

Nanba

Toyooka²,

Soh³

et al. 2008

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…Vogelsang et al (2012) reported that the MSH3 rs26279 G/G versus A/A or G/A genotype was positively associated with esophageal cancer. Hirata et al (2008) found that the G/G or G/A genotype of the MSH3 rs26279 polymorphism might be a risk factor for sporadic prostate cancer. Moreover, the genetic variant of the MSH3 rs26279/MSH6 Gly39Glu -AA/ TC was associated with a decreased risk for breast cancer (Conde et al, 2009).…”

Section: Discussionmentioning

confidence: 95%

“…The association of MSH3 gene polymorphisms in ovarian cancer has also been reported, which suggests that MSH3 polymorphism may be a risk factor for ovarian cancer (Song et al, 2006). Hirata et al (2008) investigated MMR polymorphisms in sporadic prostate cancer. They found evidence for an increased risk of sporadic prostate cancer with single nucleotide polymorphisms (SNPs) in the MSH3 variants rs1805355 and rs26279.…”

Section: Introductionmentioning

confidence: 92%

“…MMR genes play an important role in removing DDP-DNA adducts and mutation in MMR genes may lead to a decreased response to platinum-based chemotherapy (Conde-Pérezprina et al, 2012). The MSH3 gene is located on chromosome 5q11-13 and was first described in 1989 (Hirata et al, 2008); somatic mutation of MSH3 occurs frequently in MMR-deficient cancers, such as colon carcinoma (Takahashi et al, 2011;Park et al, 2013), lung cancer, breast cancer (Conde et al, 2009) and oral squamous cell carcinoma (Mondal et al, 2013). The association of MSH3 gene polymorphisms in ovarian cancer has also been reported, which suggests that MSH3 polymorphism may be a risk factor for ovarian cancer (Song et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

Yao

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Mismatch repair (MMR) genes, as well as the nucleotide excision repair genes, play an important role in removing cisplatin-DNA adducts, and the mutation of MMR genes in tumors can lead to a decreased response to platinum-based therapies. We examined MutS homolog 3 (MSH3), a mismatch repair gene, and whether polymorphisms of MSH3 were associated with response and survival in advanced non-small cell lung cancer (NCSLC) patients who were treated with platinum-based chemotherapy. The peripheral blood of 180 advanced NCSLC patients who were treated with first-line platinum-based chemotherapy was collected to determine the patients' genotypes of MSH3. The three genotypes of the MSH3 polymorphisms rs26279, rs1650697 and rs1105524 were investigated. A statistically significant association was observed between the polymorphism (2015) rs26279 (Ala1054Thr) and sensitivity to platinum-based chemotherapy (P = 0.014). A significant correlation was found between rs1105524 and progression-free survival (PFS), with the G/A and A/A genotypes (median survival time: 14.27 months; 95%CI = 9.80-18.75) suffering shorter survival than patients with the G/G genotype (median survival time: 26.37 months; 95%CI = 15.03-37.71) (P = 0.04). Our results showed that single nucleotide polymorphisms in MSH3 had an impact on the chemotherapy response and prognosis of advanced NCSLC patients who were treated with platinum-based chemotherapy.

show abstract

“…In addition to alterations that affect the function of single genes, mutations in some loci lead to alterations of multiple genes. While this concept has been best exemplified by defects in the mismatch repair genes that lead to increased genomic instability by accumulation of replicative errors in multiple genes [24,25], it is likely that altered mRNA processing, stability and translation also impact the function of many genes.…”

Section: Prostate Cancermentioning

confidence: 99%

Alternative Splicing in Prostate and Breast Cancer

Watson¹,

Watson²

2010

TOCJ

View full text Add to dashboard Cite

UAb stract: Alternative splicing of mRNA precursors allows the synthesis of multiple mRNAs from a single primary transcript, thus contributing to proteomic diversity in higher eukaryotes. Multiple studies demonstrate that alternative splicing patterns are altered during cancer progression. Several different mechanisms can contribute to changes in the regulation of alternative splicing. This report will provide an overview of how splicing microarrays and large-scale sequencing are being used to identify splicing changes in breast and prostate cancer. Global analyses of splice variants have identified cancer-specific splice variant patterns that have potential use as biomarkers and potentially have prognostic value as well as may represent novel therapeutic targets. A description of specific splice variants with differential expression in these cancers and their possible functions will be presented.

show abstract

Mismatch Repair Gene MSH3 Polymorphism is Associated With the Risk of Sporadic Prostate Cancer

Cited by 33 publications

References 19 publications

The allelic distribution of a single nucleotide polymorphism in the PDCD5 gene locus of Japanese non-small cell lung cancer patients

The allelic distribution of a single nucleotide polymorphism in the PDCD5 gene locus of Japanese non-small cell lung cancer patients

Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

Alternative Splicing in Prostate and Breast Cancer

Contact Info

Product

Resources

About